About Us
Redefining Cancer Care —
for Women, by Design.
We are GAIASO Theranostics: a pioneering biotech company dedicated to making female cancers curable.
Our Name
Inspired by Gaia, Iaso, and Hera — reflects our commitment to rapidly develop diagnostics and therapeutics for female cancers with unmet needs.
Our Purpose
GAIASO exists to change outcomes for female cancers and make them curable.
Our Vision
GAIASO Theranostics creates better solutions for women with cancer by leading the way in molecular targeted radiotherapy. We aim to eliminate treatment gaps, accelerate breakthroughs, and redefine oncology for women.
Our Mission
GAIASO Theranostics designs and develops next-generation theranostic products, combining cutting-edge technology with molecular and clinical expertise to rapidly advance new solutions for women with cancer. We change paradigms by combining therapies, enabling earlier and more precise diagnoses, and disrupting traditional development pathways. We engage all stakeholders — from patients to clinicians — to deliver the treatments women deserve, faster.
GAIASO believes in a patient-led, female-focused approach to oncology, powered by science, that will dramatically improve cancer outcomes for women.
Our Values
-
Female patients first
-
Scientific boldness
-
Speed with purpose
-
Compassion and responsibility
Led by Science. Driven by Purpose.
GAIASO is currently completing the Board and Management Team under the leadership of our distinguished Chairperson Prof. HON Jill Hennessy.
Our Chief Medical Officer Prof. Rod Hicks is leading the scientific development of the GAIASO programs.
Prof. HON Jill Hennessy
Chairperson
Professor the Hon. Jill Hennessy GAICD is a highly respected former Victorian Minister for Health and Attorney-General, renowned for her deep expertise in health system innovation, governance, regulation, and strategic leadership. She currently chairs Western Health and the Monash Women’s Health Alliance and serves as a Director of the Hudson Institute of Medical Research and the Melbourne Theranostic Innovation Centre.
With valuable experience in commercialisation, investment, and the management of worker entitlement and disability insurance schemes, Jill has a strong track record of scaling new initiatives. A passionate advocate for advancing women’s health research and its translation into practice, she also brings a disciplined and strategic approach to guiding early-stage companies through growth and impact. Jill holds a Master of Public and International Law from the University of Melbourne.
Prof. Rod Hicks
Chief Medical Officer
“The death of my beloved grandmother from long undiagnosed metastatic breast cancer inspired me to become involved in oncological PET. My more than 30 years of working with cancer patients motivates me to find better theranostic agents for the cancers that rob women of quality and duration of life. I am excited to medically lead GAIASO Theranostics in this quest.”
Rod is a Professor of Medicine at both the University of Melbourne and Monash University and an internationally-recognized pioneer in oncological PET and therapeutic nuclear medicine. His many awards include the International Cancer Imaging Society Gold Medal, the Peter E. Valk Memorial Award for lifetime achievements in clinical PET and the Saul Hertz Award for his contribution to theranostics. His research contributions have resulted in him being inducted into the Australian Academy of Health and Medical Sciences. In 2023 he was awarded an Order of Australia (AM).
GAIASO is building on key collaborations and partnerships with:
and several other partners yet to be announced
Scientific Advisory Board
The GAIASO team is united by a shared passion for transforming the experience of diagnosis and treatment planning — and for delivering better outcomes for women with cancer.
Our research and development activities will be guided by an outstanding Scientific Advisory Board appointed by GAIASO. The Board’s composition will be publicly announced soon.